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Intestinal CD4+ T cell depletion is rapid and profound during early HIV-1 infection. This leads to a compromised mucosal barrier
that prompts chronic systemic inflammation. The preferential loss of intestinal T helper 17 (Th17) cells in HIV-1 disease is a driver
of the damage within the mucosal barrier and of disease progression. Thus, understanding the effects of new therapeutic strategies
in the intestines has high priority. Histone deacetylase (HDAC) inhibitors (e.g., panobinostat) are actively under investigation as
potential latency reversing agents in HIV eradication studies. These drugs have broad effects that go beyond reactivating virus,
including modulation of immune pathways. We examined colonic biopsies from ART suppressed HIV-1 infected individuals
(clinicaltrials.gov: NCT01680094) for the effects of panobinostat on intestinal T cell activation and on inflammatory cytokine
production. We compared biopsy samples that were collected before and during oral panobinostat treatment and observed that
panobinostat had a clear biological impact in this anatomical compartment. Specifically, we observed a decrease in CD69+ intestinal
lamina propria T cell frequency and increased IL-17A mRNA expression in the intestinal epithelium. These results suggest that
panobinostat therapy may influence the restoration of mucosal barrier function in these patients.
1. Introduction
Intestines play amajor role inmaintaining our health. Beyond
nutrient and liquid absorption, the intestines serve as a
barrier between us, our intestinal microbiome, and foreign
organisms/toxins. It is therefore expected that significant
morbidity and mortality result from intestinal disorders
like those associated with abnormal immune function (e.g.,
inflammatory bowel disease) and infectious diseases (e.g.,
various foodborne illnesses) [1, 2]. HIV-1 is an infectious
disease that has a major negative impact on the intestines.
Viral infiltration and replication in early HIV-1 infection
result in rapid and profound intestinal CD4+ T cell depletion
[3–10].This leads to a compromisedmucosal barrier and then
to chronic systemic inflammation [11].The preferential loss of
intestinal T helper 17 (Th17) cells in HIV disease is a driver
of the damage within the mucosal barrier and this damage
is not reversed during antiretroviral therapy (ART) [12]. A
key effector molecule produced byTh17 cells (as well as 𝛾𝛿 T
cells and a subset of innate lymphoid cells) is IL-17A. IL-17A is
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a multifunctional cytokine with proinflammatory properties
(e.g., neutrophil recruitment) along with a role in orchestrat-
ingmucosal barrier functions [13–15]. Given the pathogenesis
of HIV-1 in the intestines, understanding the effects of new
therapeutic strategies within this organ is a priority.
Recently, we conducted a single-arm, phase I/II clini-
cal trial designed to evaluate the therapeutic effect of the
HDAC inhibitor panobinostat on HIV-1 persistence despite
successful ART [16]. Panobinostat is a potent hydroxamic
acid HDAC inhibitor with inhibitory effects in the low
nanomolar range against class I HDAC. It was approved
in 2015 by the US Food and Drug Administration for the
treatment of multiple myeloma [17]. HDAC inhibitors, like
panobinostat, are actively under investigation as potential
latency reversing agents because HIV-1 proviruses that are
integrated into deacetylated, condensed chromatin lead to
virus recrudescence when ART is interrupted. Accordingly,
HDAC inhibitors have been extensively studied in vitro [18–
20] and in vivo [16, 21–23] for their latency reversing potential
and the results have been very promising. Furthermore,many
HDAC inhibitors have robust anti-inflammatory properties
[24]. These effects were observed in our trial cohort where
panobinostat treatment was associated with reduced levels of
peripheral blood (PB) inflammatory biomarkers (e.g., high-
sensitivity C-reactive protein, interleukin-6, matrix metallo-
proteinase 9, E-selectin, and soluble CD40 ligand) as well
as reduced expression of genes related to inflammation [25].
Because of the importance of understanding the varied
intestinal effects of HDAC inhibitors as HIV-1 therapeutics,
the study design included the collection of intestinal biopsies
from consenting participants. These paired biopsies are the
source material for this study to quantitate the biological
impact of panobinostat in the intestines of individuals during
suppressive ART.
2. Methods
2.1. Study Design and Participants. Between September 2012
and February 2014 we conducted an investigator-initiated,
single-arm, phase I/II clinical trial as previously described
(clinicaltrials.gov ID number NCT01680094) [16]. In accor-
dance with the principles of the Helsinki Declaration, the
Regional Ethics Committee for Region Midtjylland and the
Danish Data Protection Agency approved the study design
prior to patient enrollment and each patient provided written
informed consent before any study procedures. FifteenHIV-1
infected adults were enrolled in the study. These individuals
exhibited virological suppression (<50 copies per mL, at least
two measurements per year) for at least 2 years and CD4+
T cell counts above 500 cells per 𝜇L. Each patient received
oral panobinostat 20mg three times per week every other
week for eight weeks while maintaining ART (Figure 1).
Study exclusion criteria included coinfection with hepatitis B
or C viruses, clinically significant cardiac disease (including
QTc prolongation), and current use of a protease inhibitor
(because of potential drug interactions). Of the 15 patients,
9 individuals (all infected with Clade B virus) consented
to participate in an endoscopic substudy with collection of
mucosal biopsies from the sigmoid colon in the week prior
Baseline Follow-
up
7 14 21 28 35 42 490
Time (days)
Panobinostat dosing weeks
Uninterrupted ART
Intestinal biopsy/peripheral blood collection interval
Panobinostat dosing days (20mg oral)
Figure 1: Schematic representation of the trial design.The timing of
panobinostat dosing and the collection of samples utilized in these
analyses are illustrated.
to panobinostat dosing and during the fourth dosing week
(Figure 1).The biopsies from the fourth week of panobinostat
treatment period were collected between 22 and 24 hours
after the most recent oral panobinostat dose.
2.2. Sigmoid Biopsies and Isolation of Lamina Propria
Mononuclear Cells (LPMCs). Sigmoidoscopy was performed
by the same experienced endoscopists at baseline and during
the fourth week of panobinostat treatment. An Olympus
Exera II CLV-180 with an Olympus GIF-H180 scope (Olym-
pus, Tokyo, Japan) was used to perform the procedures. The
sigmoidoscopies were done without prior bowel cleaning.
During all endoscopies mucosal tissue samples were taken
from a standardized location in the sigmoid colon (approxi-
mately 35 cm from the anal verge). Endoscopic biopsies were
collected for multiple analyses from macroscopically normal
intestinal mucosa. Two biopsies were randomly selected to
be fixed in 4% PFA (6–12 hours at room temperature) and
embedded in paraffin blocks for gross histopathology. The
remaining biopsies were collected in ice-cold Dulbecco’s
phosphate buffered saline (PBS) and immediately placed on
ice.These biopsies were then processed to obtain lamina pro-
pria mononuclear cells (LPMCs). First, epithelial cells were
removed by three 15min incubations at 37∘C in CMF HBSS-
EDTA (calcium-magnesium freeHank’s buffered salt solution
supplemented with 2% human AB serum, 1.5mM HEPES
(Gibco Life Technologies, Auckland, New Zealand), and
2mM EDTA (Thermo Fisher Scientific/Ambion, Waltham,
Massachusetts)). After each incubation period, the epithelial
cell-containing CMF HBSS-EDTA was removed and dis-
carded. Following the thirdCMFHBSS-EDTA incubation the
tissue samples were washed in RPMI 1640 supplementedwith
10% AB serum and 1.5mM HEPES. LPMCs were then iso-
lated via a 90min incubation at 37∘C in 5mL digestionmedia
(RPMI 1640 supplemented with 10% human AB serum,
1.5mM HEPES, 0.1mg of collagenase D (Sigma-Aldrich, St.
Louis, Missouri), and 50U/mL DNase I (Sigma-Aldrich)).
Following digestion, LPMC-containing supernatants were
collected via filtration through a 70𝜇m nylon mesh (BD
Biosciences, San Jose, California). Viable cells were counted
and then aliquoted for quantitative PCR and flow cytometry
analyses.
2.3. Quantification of Viral DNA. For four patients (identified
as 󳵳, e, ◼, and X in figures), LPMCs were used to isolate
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CD4+ T cells using a CD4+ T cell isolation kit (Miltenyi
Biotec, #130-096-533) and magnetic-activated cell sorting
(MACS) columns (purity > 95%). The goal was to gain
more specific insights into these potential viral reservoir
cells. However, the total cell yields from these four isolations
were low and therefore CD4+ T cell enrichment was not
performed with biopsies from the remaining five patients
(identified as 󳵻, l, ◻, ×, and ‰ in figures). To compare
anatomical compartments, PB CD4+ T cells collected on the
nearest date to the time of biopsy were analyzed for viral
DNA load by the same method used for the LPMCs. Isolated
LPMCs, LP CD4+ T cells, and PB CD4+ T cells to be used
for nucleic acid quantification were lysed in RLT Plus Buffer
immediately following isolation and the lysates were stored
at −80∘C until DNA was extracted (Allprep isolation kit,
Qiagen #80204). Just prior to extraction, the lysates were
subjected to shredding (Qiashredder, Qiagen #79656) and
then nucleic acids were extracted according tomanufacturer’s
instructions with each nucleic acid sample being eluted with
three repeated applications of the same 50 𝜇L elution buffer
aliquot to their respective columns.
HIV-1 DNA was quantified in samples obtained from
both the intestinal biopsies and PB cells at baseline and
on panobinostat essentially as described [26, 27]. Briefly,
extracted DNA was used directly for HIV-1 DNA quantifica-
tions using the QX100 Droplet Digital PCR system (BioRad)
(∼100 ng total DNA per PCR replicate) to determine the
absolute levels of total HIV-1 DNA per 106 LPMCs, LP CD4+
T cells, or PB CD4+ T cells. The PCR reaction mixture was
loaded into the BioRad QX100 emulsification device frac-
tionating each sample into ∼20,000 nanoliter-sized droplets
according to the manufacturer’s instructions. After cycling,
droplet data were collected using QX100 droplet reader
(BioRad) and then analyzed with the QuantaSoft analysis
software (BioRad). No panobinostat-associated cohort-wide
changes inHIV-1 DNA levels were observed in intestinal cells
(𝑝 = 0.91) (similar to [23]) or in time-matched PB CD4+ T
cells (𝑝 = 0.57) (consistent with our previous report [16]).
2.4. Cell Surface and Intracellular Cytokine Flow Cytometry
Analyses. LPMCs surface expression of the T cell activa-
tion markers was measured essentially as described [28].
Briefly, within one hour of the isolation, cells were incubated
with heat-inactivated mouse serum (Invitrogen, cat. number
10410) for 10min and then stained with CD3 PerCP (BD
Biosciences, cat. number 345766), CD4 PE (BD Pharmin-
gen, cat. number 555347), CD8 PE-Cy7 (BD Pharmingen,
cat. number 557746), CD69 APC (Biolegend, cat. number
310910), and HLA-DR APC-Cy7 (Biolegend, cat. number
307618). Following staining, the cells were fixed in 250𝜇LPBS
containing 1% formaldehyde.
Intracellular cytokine detection in LPMCswas performed
essentially as described [28]. Briefly, freshly isolated cells were
incubated unstimulated overnight at 37∘C in flat-bottomed
wells (Nunc, Denmark, cat. number 140675) at a concen-
tration of 2 × 106 LPMCs/mL in 2mL of culture medium
(RPMI 1640 with 10% pooled heat-inactivated human AB
serum, 100U/mL penicillin, and 100𝜇g/mL streptomycin).
Following this incubation, the cells were stimulated for
4 hours at 37∘C with 1 𝜇g/mL ionomycin (Sigma-Aldrich,
Denmark, cat. number I0634) and 50 𝜇g/mL phorbol-12-
myristate-13-acetate (PMA) (Sigma-Aldrich, Denmark, cat.
number P1585) in the presence of 10 𝜇g/mL brefeldin A
(Sigma-Aldrich, Denmark, cat. number B7651). Next, cells
were incubated with antibodies to detect surface expression
of CD3 FITC (BD Biosciences, cat. number 345764) and CD8
PE-Cy7 (BD Pharmingen, cat. number 557746). Following
surface staining, the cells were fixed with 1.5mL BD FACS
Lysing Solution (BD Biosciences, cat. number 349202) and
then the cells were permeabilized with 0.5mL FACS Perme-
abilizing Solution 2 (BD Biosciences, cat. number 340973).
Blocking was performed with heat-inactivated mouse serum
(Invitrogen, cat. number 10410) prior to staining with IFN-𝛾
PE (eBioscience, cat. number 12-7319) and anti-IL-17A APC
(eBioscience, cat. number 17-7179-42). Following intracellu-
lar staining, the cells were fixed in 250 𝜇L PBS containing 1%
formaldehyde.
For all samples, data were collected using a FACSCanto
analyzer (BDBiosciences) within 24 hours of staining. A total
of 105 events in the forward-side scatter lymphocyte gate were
recorded. Single cells (according to forward-scatter-height
and forward-scatter-area) were gated for CD3 expression.
CD3+ cells were next gated for CD4+, CD8+, or CD8neg,
as indicated in the figures. The cell populations were then
assessed for expression of cellular activation markers and
intracellular cytokines. Gates for CD69-, HLA-DR-, IFN-
𝛾-, and IL-17A-positive events were based upon isotype or
fluorescence-minus-one controls. Data from each patient
from both time points were batch analyzed using FlowJo v.10
(Treestar).
2.5. In Situ Hybridization (ISH). In situ hybridization for
IFN-𝛾, IL-1𝛽, IL-8, and IL-17A mRNA as well as for HIV-
1 RNA was performed in formalin-fixed paraffin-embedded
(FFPE) tissues using the RNAScope 2.0 RED assay (cat.
number 310036) according to themanufacturer’s instructions
(Advanced Cell Diagnostics, Inc., Hayward, CA, USA). First,
4 𝜇m sections were cut from FFPE blocks and mounted on
Superfrost Plus microscope slides. Consecutive sections were
mounted and a minimum separation distance of 12 𝜇m was
ensured for the sections hybridized with a given probe (2
sections per probe). Slides were placed at 60∘C for 1 hr in a dry
oven. Mounted sections were deparaffinized in xylene, dehy-
drated in 100% ethanol, and then treated serially with ACD
Pretreatment 1 (endogenous hydrogen peroxidase block)
for 10 minutes at room temperature; ACD Pretreatment 2
(boiling in citrate buffer) for 8–12 minutes at 98–100∘C; and
ACD Pretreatment 3 (protease digestion) for 12–30 minutes
at 40∘C. Note that Pretreatment 2 and 3 conditions for each
paraffin block were optimized to maximize the signal-to-
noise ratio using positive (Hs-PPIB cat. number 313901) and
negative (DapB cat. number 310043) control RNA probes.
Washes with deionized water were performed after each
pretreatment step. Next, hybridization between the target
RNA and the selected ACDprobe set (Hs-IL-17A cat. number
310931; Hs-IFN-𝛾 cat. number 310501; Hs-IL-8 cat. number
310381; Hs-IL1𝛽 cat. number 310361; V-HIV1-CladeB cat.
number 416111) took place at 40∘Cduring a 2-hour incubation
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Figure 2: Continued.
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Figure 2: Panobinostat treatment was associated with reductions in the proportions of CD69+ intestinal T cells. (a–h) Flow cytometric
analyses were performed on freshly isolated LPMCs. Intestinal CD4+ T cells (a-b; e-f) and CD8+ T cells (c-d; g-h) were assessed for CD69
(a–d) or HLA-DR (e–h) expression. The proportion of cells expressing the respective activation marker is graphed in the left column while
the levels of marker expression are represented in the right column. Each patient participant is represented in all figures by the same distinct
symbol. Wilcoxon matched-pairs signed rank tests were used to generate the reported 𝑝 values.
in a HybEZ Oven (Advanced Cell Diagnostics, Hayward,
CA). Two 2min washes with ACDwash buffer were followed
by signal amplification via the serial application of Amplifica-
tions 1–6 with two 2min wash buffer washes after each step.
Chromogenic detection of the target RNA was performed
using Fast Red (10min) followed by counterstaining with
hematoxylin and mounting with Ecomount.
2.6. Quantification of ISH Signals. All of the sections were
blinded before quantification and all counts were performed
by the same individual via visual inspection with com-
pound light microscopy with a robotic stage that ran-
domly selected areas for quantification (Visiopharm New-
Cast, version 5.0.3.1247). In a minimum of 35 systematic ran-
dom selected, nonoverlaying 25.600 𝜇m2 (160 𝜇m × 160 𝜇m)
counting frames the number of positive cell profiles was
counted. Test points were used to determine the area of exam-
ined tissue and the nature of the tissues within the counting
frame (e.g., epithelial region, lamina propria) was recorded
to allow for stratification of the data by anatomical region. In
accordance with a recommendation from ACD, a cell profile
was defined as RNA positive if it had at least one red spot
visible at 20x magnification. Ratios were calculated for each
of the probes and the background was subtracted. ISH data
are expressed as positive cell profiles per mm2. Validation
of the ISH quantification strategy was performed according
to standard methods. Briefly, all sections were counted prior
to unblinding. After all sections were counted, 25 sections
that covered all probe sets were assigned for recount prior to
unblinding of the individual performing the quantification.
These two count values for the same section (C1 and C2)
were first plotted in a C1/C2 plot and a linear regression was
performed (𝑟2 = 0.36). Next, the C1 and C2 values were
compared using an unpaired 𝑡-test (𝑝 = 0.31). Finally, a
Bland-Altman plot was generated using the average of the two
counts versus the difference between the two counts (bias =
19.1; SD = 59.5). Together these values demonstrate that
consistency in performing the quantification was maintained
throughout the entire counting process. Note that the area
measurements reported will not be the same as the true
parameters present in vivo given that paraffin embedding
and preparation caused an unavoidable, 30–50% shrinkage of
tissue [29, 30]. One goal in this project was to quantify the
number of cell profiles exhibiting productive HIV-1 infection
via ISH in the intestinal tissues collected from these patients.
Unfortunately, the lownumber of cell profileswith productive
infection identified in the examined tissue sections precluded
drawing conclusions regarding the ability of panobinostat
treatment to induce viral RNA production in the intestines.
2.7. Statistics. All statistical tests were performed using an
alpha level of 0.05. Wilcoxon matched-pairs signed rank
tests were utilized to assess whether there was a significant
difference between the baseline and on-treatment measures.
3. Results and Discussion
3.1. Panobinostat Treatment Reduced Intestinal T Cell Activa-
tion In Vivo and Augmented IFN-𝛾 Production by Intestinal
T Cells Stimulated Ex Vivo. Given our previous findings
regarding the general anti-inflammatory activity of panobi-
nostat in blood obtained from these patients [25, 31], we
examined the activation status of freshly isolated LPMCs
at baseline and during panobinostat treatment for surface
6 Mediators of Inflammation
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Figure 3: Intestinal T cells exhibit reduced intracellular IFN-𝛾 expression following ex vivo stimulation. (a–f) LPMCs were stimulated ex
vivo with PMA/ionomycin and then assessed for intracellular cytokine expression. Intestinal CD8+ T cells (a and b) and CD8neg T cells (c–f)
were assessed for INF-𝛾 (a–d) or IL-17A (e and f) expression. The proportion of cells expressing the respective cytokine is graphed in the
left column while the levels of cytokine expression are represented in the right column. Patient × and Patient 󳵳 were excluded from the
intracellular cytokine expression analyses due low cell yields that precluded performance of the ex vivo stimulation either at the “baseline” or
“during panobinostat” time point, respectively. Each patient participant is represented in all figures by the same distinct symbol. Wilcoxon
matched-pairs signed rank tests were used to generate the reported 𝑝 values.
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Figure 4: Intestinal IL-17AmRNA expression increased with panobinostat treatment. Representative images for IL-17A RNAScope ISH from
Patient ‰ are presented. Red arrowheads indicate a sampling of mRNA positive cell profiles in each image. Dashed lines demarcate lamina
propria (LP) and epithelial (E) regions.
expression of early (i.e., CD69) and late (i.e., HLA-DR) T
cell activation molecules [32]. We observed a decrease in
the proportion of CD69+ intestinal CD4+ and CD8+ T cells
(𝑝 = 0.004, Figure 2(a); 𝑝 = 0.020, Figure 2(c), resp.).
Althoughwewere unable to definitely determinewhether this
change resulted from decreased activation of resident cells
versus an influx of naive cells, we did observe a significant
decrease in the expression levels of CD69 on the intestinal
CD4+ T cells (𝑝 = 0.008, Figure 2(b)) and a trend towards
reduced CD69 expression on intestinal CD8+ T cells (𝑝 =
0.055, Figure 2(d)). In contrast to our findings regarding
CD69 expression on intestinal T cells, we did not observe
changeswith panobinostat dosing in the proportions ofHLA-
DR expressing intestinal T cells or in the expression levels
of HLA-DR on intestinal T cells (Figures 2(e) and 2(f)).
It should be noted that these results from intestinal cells
differ from PB outcomes from these patients [31]. Notable
distinctions are that the baseline proportion of CD69+ T
cells in the intestines is considerably higher than in the
PB, as expected [33], and that the greatest increase in the
proportion of activated CD4+ T cells was observed in PB
during the first dosing week, while the observations made
in the intestines are from the last dosing week. Thus, the
differences between the observations in the intestines and PB
regarding T cell activationmay reflect differential stimulatory
environments between these two anatomical compartments
and the differential in the timing of the observations relative
to the course of panobinostat treatment.
Next, we performed an ex vivo mitogenic stimulation
of LPMCs that were rested overnight following isolation.
We examined CD8+ and CD8neg T cells for intracellular
expression of two proinflammatory cytokines (i.e., IFN-𝛾 and
IL-17A) [34]. We did not observe changes in the proportions
of IFN-𝛾-producing intestinal T cells (Figures 3(a) and 3(c)).
However, we did observe decreases in the expression levels of
IFN-𝛾 in both intestinal CD8+ and CD8neg T cells (𝑝 = 0.016,
Figure 3(b); 𝑝 = 0.031, Figure 3(d), resp.). Overexpression of
IFN-𝛾 and other type 1 interferons in T lymphocytes has been
observed both in experimental animalmodels of colitis and in
patients with ulcerative colitis [35]. Thus, the detected reduc-
tion in IFN-𝛾 expression could reflect a general pleiotropic
anti-inflammatory effect of panobinostat on lamina propria-
resident T lymphocytes. This reduction in expression does
not readily conform to our observation that panobinostat
treatment generally did not affect IFN-𝛾 secretion by PB
CD8+ T cell memory subsets from this patient cohort [36].
However, direct comparisons between these PB and intestinal
cell analyses are challenging. The main reasons are the dif-
ference in timing of sample selection as noted above and the
fact that the ex vivo stimulationswere performedwith staphy-
lococcal enterotoxin B (SEB) antigen for the PB cells and
PMA/ionomycin for the intestinal cells. Further, the blood
analyses were stratified bymemory subset providing different
assay resolution. IL-17A production was not examined in the
PB cells, but it was characterized for the intestinal CD8neg
T cells in response to mitogen stimulation. In this analysis,
we did not observe cohort-wide changes in the proportion of
cells expressing IL-17A or in the per cell expression (𝑝 = 0.22,
Figure 3(e); 𝑝 = 0.94, Figure 3(f), resp.). In accordance with
the anticipated anti-inflammatory activity of panobinostat,
these analyses demonstrate that panobinostat dosing gener-
ally reduced expression of the activation marker CD69 on
intestinal T cells and reduced the capacity of intestinal T cells
to produce IFN-𝛾 in response to ex vivo stimulation.
3.2. The Number of IL-17A mRNA Producing Intestinal Cell
Profiles Increased in the Epithelial Region with Panobinostat
Dosing. To gain insights into changes in the numbers of indi-
vidual cells producing cytokinemRNA in the intestine during
panobinostat therapy, we performed quantitative RNA in situ
hybridization using limited amounts of biopsy material with
the assumptions that these tissue samples were representative
for the whole intestine and that two-dimensional profile
counts correlate with total cell counts. Analyses were strati-
fied according to the anatomical region harboring the RNA
expressing cells (i.e., lamina propria and epithelial regions).
We found that panobinostat treatment was associated with a
significant increase in the number of cell profiles (𝑝 = 0.04)
exhibiting IL-17A production within the epithelial region but
not the lamina propria (𝑝 = 0.13) (Figures 4, 5(a), and 5(b)).
In contrast, we did not observe cohort-wide differences in
the number of cell profiles exhibiting INF-𝛾, IL-8, or IL1𝛽
8 Mediators of Inflammation
Baseline 4th panobinostat
dosing week
Lamina propria regions
IL
-1
7A
p = 0.13
0
50
100
150
Po
sit
iv
e c
el
l p
ro
fil
es
 p
er
 m
m
2
(a)
Baseline 4th panobinostat
dosing week
Epithelial regions
p = 0.04
IL
-1
7A
Po
sit
iv
e c
el
l p
ro
fil
es
 p
er
 m
m
2
0
50
100
150
200
(b)
Baseline 4th panobinostat
dosing week
Lamina propria regions
p = 0.63
IF
N
-𝛾
Po
sit
iv
e c
el
l p
ro
fil
es
 p
er
 m
m
2
0
50
100
150
(c)
Baseline 4th panobinostat
dosing week
Epithelial regions
p = 0.31
IF
N
-𝛾
Po
sit
iv
e c
el
l p
ro
fil
es
 p
er
 m
m
2
0
50
100
150
(d)
Baseline 4th panobinostat
dosing week
Lamina propria regions
IL
-8
p = 0.25
Po
sit
iv
e c
el
l p
ro
fil
es
 p
er
 m
m
2
0
50
100
150
(e)
Baseline 4th panobinostat
dosing week
Epithelial regions
p = 0.58
IL
-8
0
100
200
300
400
Po
sit
iv
e c
el
l p
ro
fil
es
 p
er
 m
m
2
(f)
Figure 5: Continued.
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Figure 5: Epithelial region of intestines harbored the cells exhibiting IL-17A mRNA expression increase during panobinostat treatment. In
situ hybridization for cytokine mRNA was performed with RNAScope technology. (a–h) Plots depict the number of cell profiles producing
mRNA for IL-17A (a and b), IFN-𝛾 (c and d), IL-8 (e and f), and IL-1𝛽 (g and h) at baseline and during panobinostat. Left column depicts
positive cell profiles per mm2 within the lamina propria regions. Right column depicts positive cell profiles per mm2 within the epithelial
regions. Patient 󳵻 was excluded from the final analyses due to insufficient tissue for both optimization and assay performance. Each patient
participant is represented in all figures by the same distinct symbol. Wilcoxon matched-pairs signed rank tests were used to generate the
reported 𝑝 values.
production in either the lamina propria or the epithelial
regions of the intestine (Figures 5(c)–5(h)). The results for
intracellular and in situ IL-17A expression (Figures 3(e),
3(f), 4, 5(a), and 5(b)) may appear to be contradictory at
first glance. The likely explanation is that these observations
highlight key methodological differences in the two assays.
Specifically, the intracellular cytokine secretion assay was
performed on isolated LPMCs. The sample preparation used
for this analysis excluded the intraepithelial layer from
assessment. In contrast, the in situ hybridization technique
allowed quantitation throughout both the lamina propria and
epithelial regions. Using this method and taking the stated
assumptions into account, we were able to determine that
the epithelial regions were the anatomical location of the
increased IL-17A expression (Figure 5(b)).
IL-17A expression in the intestines is frequently associ-
ated with inflammatory processes, such as in inflammatory
bowel disease [15, 37–41]. However, IL-17A also induces
robust production of antimicrobial peptides important for
maintaining the intestinal epithelial barrier [42]. IL-17A is
produced by intestinal innate lymphoid cells to orchestrate
mucosal barrier function [13], exhibits anti-inflammatory
behavior in the context of cultured human colonic epithelial
cells [43], and ameliorates inflammation in rodent colitis
models [43, 44]. Thus the data presented here lead us to
hypothesize that the panobinostat-induced upregulation in
IL-17A mRNA observed in the intestinal epithelium is asso-
ciated with mucosal barrier restoration. Such activity would
be consistent with the general anti-inflammatory activity of
panobinostat in these same patients [25], reduced LPMC
T cell activation (Figures 2(a)–2(d)), reduced levels of IFN-𝛾
production following ex vivo stimulation (Figures 3(a)–3(d)),
and the unchanged intestinal IFN-𝛾, IL-8, and IL1𝛽 mRNA
levels (Figures 5(c)–5(h)). Future studies are necessary to
confirm that the panobinostat-induced IL-17A expression
in the intestinal epithelium is indicative of mucosal barrier
restoration and a reduction of chronic immune activation in
HIV patients during suppressive ART. With such confirma-
tion, perhaps panobinostat (or similarly acting compounds)
could become therapeutic options for reducing morbidity
associated with chronic inflammation in these individuals.
3.3. Conclusions. It is essential that conclusions are cautiously
drawn from these data as they are derived from a single-arm
phase I/II clinical study with increased peripheral blood cell-
associated unspliced-HIV-1 RNA during panobinostat treat-
ment as the primary endpoint. Nevertheless, these data do
lend themselves to a key conclusion. Panobinostat has a clear
biological impact in the intestines of HIV-1 patients as shown
by the decreased CD69+ intestinal T cell frequency and
increased IL-17A expression in the intestinal epithelium asso-
ciated with panobinostat treatment. The significance of this
last finding could be profound if future studies confirm that
panobinostat dosing leads to improvedmucosal barrier func-
tion in the intestines of HIV patients during suppressive ART.
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